Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01983241 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)
A Phase 3 study of Pulmonary Emphysema in Alpha-1 PI Deficiency, sponsored by Grifols Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 345
- Enrollment target
- 20
- Study locations
NCT01983241: Active Phase 3 study of Pulmonary Emphysema in Alpha-1 PI Deficiency, sponsored by Grifols Therapeutics.
NCT01983241 is a Phase 3 study of Pulmonary Emphysema in Alpha-1 PI Deficiency that is active but no longer recruiting, run by Grifols Therapeutics. The registered enrollment target is 345 participants. The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01983241, a Phase 3 study of Pulmonary Emphysema in Alpha-1 PI Deficiency, is active but no longer recruiting, sponsored by Grifols Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 345 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multi-center, randomized, placebo-controlled, double blind clinical study to assess the efficacy and safety of two separate dose regimens of Alpha-1 MP versus placebo for 156 weeks (i.e., 3 years) using computed tomography (CT) of the lungs as the main measure of efficacy. The two Alpha-1 MP doses to be tested are 60 mg/kg and 120 mg/kg administered weekly by IV infusion for 156 weeks. The study consists of an optional pre-screening phase, Screening Phase, a 156-week Treatment Phase, and an End of Study Visit at Week 160.
Conditions Studied
Interventions
- BIOLOGICAL Alpha-1 MP
- OTHER 0.9% Sodium Chloride for Injection, USP
Study Locations (20)
Florida
- Grifols Investigative Site - Gainesville
- Grifols Investigative Site - Leesburg
- Grifols Investigative Site - Miami
São Paulo
- Grifols Investigative Site - Santo André
- Grifols Investigative Site - São Paulo
- Grifols Investigative Site - São Paulo
Arizona
- Grifols Investigative Site - Phoenix
Missouri
- Grifols Investigative Site - St Louis
North Carolina
- Grifols Investigative Site - Wilmington
Oregon
- Grifols Investigative Site - Portland
Pennsylvania
- Grifols Investigative Site - Hershey
South Carolina
- Grifols Investigative Site - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 345 participants |
| Start Date | 2013-11 |
| Est. Completion | 2027-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01983241
The ClinicalTrials.gov registry entry for NCT01983241 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 345 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Grifols Therapeutics, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Emphysema in Alpha-1 PI Deficiency appearing as the primary indexed condition, and to 2 interventions - of which Alpha-1 MP is the first listed.
NCT01983241 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Florida, São Paulo, Arizona.
Frequently Asked Questions
What is clinical trial NCT01983241 about?
NCT01983241 is a clinical study titled "Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)". This is a multi-center, randomized, placebo-controlled, double blind clinical study to assess the efficacy and safety of two separate dose regimens of Alpha-1 MP versus placebo for 156 weeks (i.e., 3 years) using computed tomography (CT) of the lungs as the main measure of efficacy. The two Alpha-1 ...
What is the current status of trial NCT01983241?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 345 participants. The study started on 2013-11. Estimated completion is 2027-01.
What conditions does trial NCT01983241 study?
This clinical trial studies the following conditions: Pulmonary Emphysema in Alpha-1 PI Deficiency.
What interventions are being tested in trial NCT01983241?
The interventions under investigation include: Alpha-1 MP (BIOLOGICAL), 0.9% Sodium Chloride for Injection, USP (OTHER).
Who is sponsoring clinical trial NCT01983241?
This trial is sponsored by Grifols Therapeutics, which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01983241 being conducted?
This trial has 20 study locations across Arizona, Florida, Missouri, North Carolina, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.